Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 and 2 Study of PX-866 and Cetuximab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01252628
Recruitment Status : Completed
First Posted : December 3, 2010
Last Update Posted : May 16, 2018
Sponsor:
Information provided by (Responsible Party):
Seagen Inc. ( Cascadian Therapeutics Inc. )

Tracking Information
First Submitted Date  ICMJE December 1, 2010
First Posted Date  ICMJE December 3, 2010
Last Update Posted Date May 16, 2018
Study Start Date  ICMJE December 2010
Actual Primary Completion Date November 2013   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 12, 2011)
The evaluation of antitumor effects of PX-866 in combination with cetuximab versus cetuximab in patients with incurable metastatic colorectal cancer and/or patients with incurable progressive, recurrent or metastatic SCC of the head and neck. [ Time Frame: 21 days ]
Original Primary Outcome Measures  ICMJE
 (submitted: December 1, 2010)
Determine the maximally tolerated (MTD) or recommended (RD) Phase 2 dose of PX-866 to be administered orally once per day in combination with cetuximab. [ Time Frame: 21 days ]
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase 1 and 2 Study of PX-866 and Cetuximab
Official Title  ICMJE Phase 1/2 Study of PX-866 and Cetuximab
Brief Summary The purpose of this Phase 1/2 open-label study is to determine the safety and efficacy of a cetuximab and PX-866 combination treatment. In the Phase 1 part of the study, the dose of PX-866 to be given in combination with cetuximab will be determined in patients with incurable metastatic CRC or incurable progressive, recurrent or metastatic SCCHN. The Phase 2 part of the study is a randomized evaluation of the antitumor activity and safety of PX-866 in combination with cetuximab versus cetuximab alone in patients with either incurable metastatic CRC who have a history of progression or recurrence following prior irinotecan and oxaliplatin containing regimens or are intolerant of irinotecan (Group 1) or incurable progressive, recurrent or metastatic SCCHN (Group 2).
Detailed Description

Phase 1 will determine the maximally tolerated or recommended dose of PX-866 to be given orally on Days 1-21 in combination with cetuximab 250 mg/m2 administered IV weekly on Days 1, 8, and 15 of a 21-day cycle. All patients will receive an initial loading dose of 400 mg/m2 cetuximab rather than 250 mg/m2 on Cycle 1 Day 1. Patients may receive premedication with an H1 antagonist per the cetuximab package insert. Up to 3 dose levels of PX-866 will be evaluated to determine the MTD/RD in cohorts of up to 6 patients using a standard 3+3 dose-escalation design. At least 6 patients will be treated at the MTD/RD. All patients in Phase 1 will be required to undergo PK assessments during Cycle 1 Week 3 to measure cetuximab levels. Exploratory PD assessments will include evaluation of changes in levels of fasting C-peptide as well as changes in EGFR and PI-3K signaling pathways in peripheral blood mononuclear cells (PBMC) and platelets. Additional optional evaluations will include changes in EGFR and PI-3K signaling in paired tumor biopsies provided before and after one cycle of treatment. All patients will be asked, but not required, to provide an archived tumor biopsy sample for evaluation for potential biomarkers of response to PX-866 and cetuximab.

Phase 2 is an open-label, randomized evaluation of the antitumor activity and safety of PX-866 administered orally or via PEG tube (if applicable) at the MTD/RD in combination with cetuximab, versus cetuximab alone in cetuximab-naïve patients with incurable metastatic CRC who have a history of progression or recurrence following prior irinotecan and oxaliplatin containing regimens or are intolerant of irinotecan (Group 1) or patients with incurable progressive, recurrent or metastatic SCCHN (Group 2). Seventy two evaluable patients (36 patients per arm) will be evaluated per indication. Patients will be randomized 1:1 to receive PX-866 + cetuximab or cetuximab alone.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Incurable Metastatic Colorectal Carcinoma
  • Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Intervention  ICMJE
  • Drug: PX-866 (SCCHN)
    PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
  • Drug: Cetuximab (SCCHN)
    Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
    Other Name: Erbitux
  • Drug: PX-866 (CRC)
    PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
  • Drug: Cetuximab (CRC)
    Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
    Other Name: Erbitux
Study Arms  ICMJE
  • Experimental: PX-866 (SCCHN)
    Phase 2 (Squamous Cell Carcinoma of the Head and Neck)
    Interventions:
    • Drug: PX-866 (SCCHN)
    • Drug: Cetuximab (SCCHN)
  • Active Comparator: Cetuximab (SCCHN)
    Phase 2 (Squamous Cell Carcinoma of the Head and Neck)
    Intervention: Drug: Cetuximab (SCCHN)
  • Experimental: PX-866 (CRC)
    Phase 2 (Colorectal Carcinoma)
    Interventions:
    • Drug: PX-866 (CRC)
    • Drug: Cetuximab (CRC)
  • Active Comparator: Cetuximab (CRC)
    Phase 2 (Colorectal Carcinoma)
    Intervention: Drug: Cetuximab (CRC)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 31, 2011)
178
Original Estimated Enrollment  ICMJE
 (submitted: December 1, 2010)
18
Actual Study Completion Date  ICMJE January 2014
Actual Primary Completion Date November 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • At least 18 years at time of consent
  • Use of a medically accepted form of contraception from the time of consent to completion of all follow-up study visits
  • If female of child-bearing potential, negative pregnancy test
  • Signed an informed consent
  • Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST)
  • Documentation available for last prior systemic treatment including dates of treatment, best response to treatment, duration of best response, and reason for discontinuation of treatment
  • Eastern Cooperative Oncology Group (ECOG) 0 or 1
  • Group 1: Patients with incurable metastatic CRC with a history of progression or recurrence following prior irinotecan and oxaliplatin containing regimens. Patients who have a history of intolerance of irinotecan based therapy or ineligibility to receive irinotecan are also eligible as long as they have received a prior oxaliplatin containing regimen.
  • Group 2: Patients with incurable SCCHN with a history of progression or recurrence following at least one prior platinum based chemotherapy or chemotherapy/radiation containing regimen. Patients who have a history of intolerance of platinum based therapy or history of ineligibility to receive a platinum based regimen are also eligible. SCCHN patients who received cetuximab as a radiosensitizer for locally advanced disease and completed treatment at least 6 months prior to start of study drug treatment are eligible
  • In the opinion of the clinical investigator, life expectancy of greater than 3 months
  • Adequate hematologic function
  • Adequate hepatic function
  • Creatinine level ≤1.5 x ULN
  • Serum magnesium ≥ LLN.

Exclusion Criteria:

  • Has medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance with study procedures
  • Is breastfeeding
  • Treatment with any systemic chemotherapy, epidermal growth factor receptor (EGFR) inhibitor, radiation or experimental agent within 4 weeks of study drug dosing
  • Received prior cetuximab, except as defined in inclusion criteria
  • Previous treatment with a phosphatidylinositol 3-kinase (PI-3K) inhibitor
  • Known human immunodeficiency virus (HIV)
  • Poorly controlled diabetes mellitus (IFCC-HbA1C ≥ 53 mmol/mol or DCCT -HbA1C ≥ 7%)
  • Kras mutation in codon 12 or 13 (CRC patients only)
  • Known or suspected clinically active brain metastases. Previously treated and stable brain metastases are allowable. Stable brain metastases are defined as no change on CT scan or MRI for minimum of two months AND no change in steroid dose for a minimum of four weeks, unless change due to intercurrent infection or other acute event)
  • Any other significant medical or psychiatric condition that in the opinion of the investigator renders the patient inadequate for participation
  • History of severe hypersensitivity to cetuximab
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01252628
Other Study ID Numbers  ICMJE PX-866-003
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Seagen Inc. ( Cascadian Therapeutics Inc. )
Original Responsible Party Diana F. Hausman, MD / VP of Clinical Development, Oncothyreon, Inc.
Current Study Sponsor  ICMJE Cascadian Therapeutics Inc.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Diana Hausman, MD Cascadian Therapeutics Inc.
PRS Account Seagen Inc.
Verification Date June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP